1. Pink Sheet

EMA Fees: Parliamentary Committee Insists On Full Transparency & Sufficient Funding

 
• By Ian Schofield

The ENVI committee says the regulatory work done by national regulators on behalf of the European Medicines Agency must be properly remunerated to ensure “world-class pharmaceutical supervision."

Wooden cube with Fees words on stacked of coins
Fees should reflect the work actually done by EU regulators • Source: Shutterstock

A European Parliament committee has backed a draft regulation intended to simplify the fee structure at the European Medicines Agency but cautioned that the fees must be based on a “transparent evaluation” of the estimates of workload and related regulatory costs.

The environment and public health (ENVI) committee also insisted that sufficient funding was needed for both the EMA and the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

ACIP Upheaval Leaves Merck & Co. In A Lurch

 
• By Jessica Merrill and Bridget Silverman

Merck’s newly approved Enflonsia for RSV is one of the products expected to be recommended for use by the CDC Advisory Committee on Immunization Practices later this month.

‘Sex Pill For Women’: Sprout CEO’s Addyi Instagram Post Draws US FDA Warning Letter

 
• By Sue Sutter

Cindy Eckert’s social media post with a People.com story failed to include any risk information, made misleading representations about benefits and omitted material information about the indication, said the agency, which flagged similar concerns about an Addyi radio ad five years ago.

US FDA Chief Counsel Position Awaits HHS General Counsel Confirmation

 
• By Sue Sutter

Robert Foster, HHS deputy general counsel and chief counsel for food, research and drugs, is temporarily heading the Office of Chief Counsel, but a permanent appointee is expected after Michael Stuart's confirmation as HHS general counsel.